COMPANY
Kala Pharmaceuticals, Inc.
Funding and NIH signals
- SEC Form D raise Raised $1.75M (Form D filed Mar 17, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001829126-26-002408 (Mar 17, 2026)
Evidence (2 events)
- Mar 17, 2026 · SEC Form D 0001829126-26-002408
Name of Issuer: KALA BIO, Inc.; CIK: 1479419; Address: Arlington, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1753500; Total Amount Sold: 1753500; Federal exemptions: 06b - Feb 13, 2026 · SEC Form D 0001829126-26-001292
Name of Issuer: KALA BIO, Inc.; CIK: 1479419; Address: Arlington, MA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4200000; Total Amount Sold: 2250600; Federal exemptions: 06b
- Mar 17, 2026 · SEC Form D 0001829126-26-002408
Timeline
- Raise Private placement: $10.75M (total, as published), announced Dec 30, 2024. Source: SEC filing. source ↗
Funding
- Private placement: $10.75M (total, as published), announced Dec 30, 2024. Source: SEC filing. source ↗
Raises and investors new
- Raise Private raise (SEC Form D): $1.8M sold; issuer “KALA BIO, Inc.”. Verified from the SEC filing. SEC filing ↗
- Raise Private raise (SEC Form D): $2.3M sold of $4.2M offered; issuer “KALA BIO, Inc.”. Verified from the SEC filing. SEC filing ↗
- Raise Private raise (SEC Form D): $10.7M sold; issuer “KALA BIO, Inc.”. Verified from the SEC filing. SEC filing ↗